Jamilian Hamidreza, Ghaderi Amir
Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran.
Clinical Research Development Unit-Matini/Kargarnejad Hospital, Kashan University of Medical Sciences, Kashan, IR, Iran.
Biol Trace Elem Res. 2021 Dec;199(12):4430-4438. doi: 10.1007/s12011-020-02572-3. Epub 2021 Jan 6.
This study evaluated the effects of probiotic and selenium co-supplementation on clinical and metabolic symptoms in patients with chronic schizophrenia. A randomized, double-blind, placebo-controlled trial was conducted among 60 people with chronic schizophrenia to receive either 8 × 10 CFU/day probiotic plus 200 μg/day selenium (n = 30) or placebo (n = 30) for 12 weeks. Probiotic and selenium co-supplementation resulted in a significant improvement in the general Positive and Negative Syndrome Scale (PANSS) score (β - 1.29; 95% CI, - 2.48, - 0.10; P = 0.03) compared with the placebo. Compared with the placebo, probiotic and selenium co-supplementation resulted in a significant elevation in total antioxidant capacity (β 91.09 mmol/L; 95% CI, 35.89, 146.30; P = 0.002) and total glutathione (β 96.50 μmol/L; 95% CI, 26.13, 166.87; P = 0.008) and a significant reduction in high-sensitivity C-reactive protein levels (β - 1.44 mg/L; 95% CI, - 2.22, - 0.66; P = 0.001). Additionally, co-supplementation significantly decreased fasting glucose (β - 7.40 mg/dL; 95% CI, - 10.15, - 4.64; P < 0.001), insulin levels (β - 1.46 μIU/mL; 95% CI, - 2.35, - 0.57; P = 0.002), and homeostasis model of assessment-insulin resistance (β - 0.51; 95% CI, - 0.72, - 0.29; P < 0.001) and a significant increase in quantitative insulin sensitivity check index (β 0.01; 95% CI, 0.006, 0.01; P < 0.001) compared with the placebo. Probiotic and selenium co-supplementation for 12 weeks to patients with chronic schizophrenia had beneficial effects on the general PANSS score and some metabolic profiles. http://www.irct.ir , identifier IRCT20170513033941N41.
本研究评估了联合补充益生菌和硒对慢性精神分裂症患者临床及代谢症状的影响。对60例慢性精神分裂症患者进行了一项随机、双盲、安慰剂对照试验，其中30人接受8×10 CFU/天的益生菌加200μg/天的硒，另外30人接受安慰剂，为期12周。与安慰剂相比，联合补充益生菌和硒使阳性和阴性症状量表（PANSS）总分显著改善（β=-1.29；95%CI：-2.48，-0.10；P=0.03）。与安慰剂相比，联合补充益生菌和硒使总抗氧化能力显著升高（β=91.09 mmol/L；95%CI：35.89，146.30；P=0.002）、总谷胱甘肽显著升高（β=96.50μmol/L；95%CI：26.13，166.87；P=0.008），并使高敏C反应蛋白水平显著降低（β=-1.44 mg/L；95%CI：-2.22，-0.66；P=0.001）。此外，与安慰剂相比，联合补充显著降低了空腹血糖（β=-7.40 mg/dL；95%CI：-10.15，-4.64；P<0.001）、胰岛素水平（β=-1.46μIU/mL；95%CI：-2.35，-0.57；P=0.002）以及稳态模型评估-胰岛素抵抗（β=-0.51；95%CI：-0.72，-0.29；P<0.001），并使定量胰岛素敏感性检查指数显著升高（β=0.01；95%CI：0.006，0.01；P<0.001）。对慢性精神分裂症患者联合补充益生菌和硒12周对PANSS总分及一些代谢指标有有益影响。http://www.irct.ir，标识符IRCT20170513033941N41 。
